Table 1 Demographic and clinical patient data
Variable | Total N = 122 | hsPC N = 58 | CRPC N = 64 | p-Value |
|---|---|---|---|---|
Age [y] | 70.9 (± 7.6) Range: (49.0; 85.0) | 70.0 (± 7.8) Range: (50.0; 85.0) | 71.8 (± 7.3) Range: (49.0; 85.0) | 0.201 |
Tracer dose [Mbq] | 185.1 ± 19.5 Range: (134.0; 300.0) | 186.1 (± 22.0) Range: (134.0; 300.0) | 184.1 (± 17.0) Range: (149.0; 263.0) | 0.802 |
PSA [ng/mL] | 102.65 ± 448.03 Range: (0.01; 3689.0) | 6.63 (± 12.29) Range: (0.18; 51.2) | 189.67 (± 607.63) Range: (0.01; 3689.0) | < 0.001 |
DNA methylation markers | ||||
AKR1B1 [PMR] | 2.82 (± 12.52) Range: (1e-06; 80.66) | 0.00039 (± 0.00198) Range: (1e-06; 0.015) | 5.38 (± 16.94) Range: (1e-06; 80.66) | < 0.001 |
CHST11 [PMR] | 1.75 (± 8.6) Range: (0.0; 83.77) | 0.00035 (± 0.0018) Range: (0.0; 0.0113) | 3.34 (± 11.69) Range: (0.0; 83.77) | < 0.001 |
CRABP2 [PMR] | 0.49 (± 2.36) Range: (1.7e-05; 20.96) | 0.0813 (± 0.102) Range: (0.000117; 0.597) | 0.865 (± 3.22) Range: (1.7e-05; 20.96) | 0.062 |
CUGBP2 [PMR]* | 0.13 (± 1.05) Range: (0.0; 10.75) | 0.00637 (± 0.0475) Range: (0.0; 0.361) | 0.247 (± 1.46) Range: (0.0; 10.75) | 0.086 |
KLF8 [PMR] | 3.3 (± 9.73) Range: (0.00317; 45.07) | 0.238 (± 0.827) Range: (0.00317; 6.28) | 6.08 (± 12.83) Range: (0.00664; 45.07) | 0.001 |
LDAH [PMR] | 3.41 (± 11.79) Range: (4.1e-05; 71.99) | 0.0104 (± 0.0596) Range: (4.1e-05; 0.452) | 6.5 (± 15.71) Range: (4.4e-05; 71.99) | < 0.001 |
PCDHGC4 [PMR] | 2.23 (± 7.88) Range: (1e-06; 42.61) | 0.0118 (± 0.0355) Range: (1e-06; 0.254) | 4.25 (± 10.52) Range: (1e-06; 42.61) | < 0.001 |
TNFAIP8 [PMR] | 1.06 (± 5.66) Range: (0.0; 58.36) | 0.397 (± 0.675) Range: (5.5e-05; 3.69) | 1.66 (± 7.77) Range: (0.0; 58.36) | 0.737 |
PSMA-TV [cm3] | 116.5 ± 305.5 Range: (0.0; 1597.7) | 16.2 (± 86.5) Range: (0.0; 659.1) | 207.4 (± 392.8) Range: (0.0; 1597.7) | < 0.001 |
Disease extent | < 0.001 | |||
Non | 25 (20.49%) | 16 (27.59%) | 9 (14.06%) | |
Localized | 21 (17.21%) | 16 (27.59%) | 5 (7.81%) | |
Metastatic | 76 (62.3%) | 26 (44.83%) | 50 (78.12%) | |
PSMA-TV [cm3] per disease extent | ||||
Localized | 4.5 (± 4.4) Range: (0.2; 15.4) | 4.26 (± 4.1) Range: (0.2; 14.83) | 5.28 (± 5.8) Range: (0.8; 15.38) | 0.836 |
Metastatic | 185.7 (± 370.5) Range: (0.2; 1597.7) | 33.5 (± 128.4) Range: (0.2; 659.1) | 264.9 (± 427.7) Range: (0.3; 1597.7) | < 0.001 |
PSMA-positive lesions | ||||
Any lesion | 97 (79.51%) | 42 (72.41%) | 55 (85.94%) | 0.104 |
Prostate | 39 (31.97%) | 23 (39.66%) | 16 (25.0%) | 0.124 |
Lymph node | 51 (41.8%) | 19 (32.76%) | 32 (50.0%) | 0.081 |
Bone | 51 (41.8%) | 10 (17.24%) | 41 (64.06%) | < 0.001 |
Organ | 18 (14.75%) | 4 (6.9%) | 14 (21.88%) | 0.023 |
Hormonal therapies while PET | < 0.001 | |||
Yes | 48 (39.34%) | 4 (6.9%) | 44 (68.75%) | |
No | 68 (55.7%) | 51 (87.93%) | 17 (26.56%) | |
Cytotoxic therapies while PET | 0.403 | |||
Yes | 4 (3.3%) | 1 (1.72%) | 3 (4.69%) | |
No | 114 (93.4%) | 54 (93.1%) | 60 (93.75%) | |
Therapies after PET | < 0.001 | |||
Local | 29 (39.19%) | 22 (57.89%) | 7 (19.44%) | |
Local + ADT | 5 (6.76%) | 5 (13.16%) | 0 (0.0%) | |
ADT | 17 (22.97%) | 8 (21.05%) | 9 (25.0%) | |
CHT | 3 (4.05%) | 0 (0.0%) | 3 (8.33%) | |
CHT + ADT | 2 (2.7%) | 1 (2.63%) | 1 (2.78%) | |
Lu177 | 17 (22.97%) | 1 (2.63%) | 16 (44.44%) | |
Study | 1 (1.35%) | 1 (2.63%) | 0 (0.0%) | |
Time since diagnosis [y] | 5.44 ± 5.85 Range: (0.0; 21.0) N = 111 | 3.58 (± 4.67) Range: (0.0; 20.0) N = 55 | 7.27 (± 6.39) Range: (0.0; 21.0) N = 56 | < 0.001 |
Mean Follow-Up [m] | 24.88 ± 16.56 | 21.0 ± 16.33 | 29.15 ± 15.88 | 0.011 |
Range: (0.0; 58.75) | Range: (0.43; 58.75) | Range: (0.0; 51.87) |